usaKor

blog youtube naverTV instagram
검색
전체메뉴
전화예약 1577-4488
일반진료 월 화 수 목 금 토
오전
오후
진료예약

종양내과

문용화

전문분야
유방암, 부인암, 전립선암

교수 경력

  • 연세대학교
  • 차의과학대학교

진료 경력

  • 국립목포병원 내과 과장 (공중보건의 근무)
  • 연세의료원 연세암센터 종양내과 강사 및 임상연구조교수
  • 연세의료원 연세암병원 종양내과 계약교수
  • 現 차의과학대학교 분당차병원 혈액종양내과 교수

학회/연구/Postdoctorial Fellowship/수상경력

  • 학회
  • 대한내과학회 회원
  • 대한암학회 회원
  • 대한종양내과학회 회원
  • 대한종양내과학회 부인암분과 위원
  • 대한종양내과학회 비뇨기암분과 위원
  • 대한폐암학회 회원
  • 미국 암연구협회 (American Association for Cancer Research) 회원
  • 미국 임상종양학회 (American Society for Clinical Oncology) 회원

  • 연구
  • 면역인간화 마우스모델

  • Postdoctorial Fellowship
  • Post-Doctoral Fellowship, NIH/NCI, Bethesda, USA
  • Clinical Fellowship, Department of Investigational Cancer Therapeutics, UT MD Anderson Cancer Center, Huston, USA
  • 언론기사·영상
  • 논문
더보기
  1. Diagnostic cholangioscopy for surgical planning of extrahepatic cholangiocarcinoma, Scientific Reports, 2024-12, (국외)SCI
  2. Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer, JOURNAL OF HEPATOLOGY, 2024-10, (국외)SCI
  3. Oral reovirus reshapes the gut microbiome and enhances antitumor immunity in colon cancer, Nature Communications, 2024-10, (국외)SCI
  4. Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy, HEPATOLOGY, 2024-09, (국외)SCI
  5. Metabolism and macrophages in the tumor microenvironment, CURRENT OPINION IN IMMUNOLOGY, 2024-09, (국외)SCI
  6. Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries, Liver Cancer, 2024-08, (국외)SCI
  7. Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries, Liver Cancer, 2024-08, (국외)SCI
  8. Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment, HEPATOLOGY, 2024-07, (국외)SCI
  9. Distinct Characteristics and Changes in Liver Function of Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab for more than 1 Year, Cancer Research and Treatment, 2024-05, (국외)SCI
  10. Prognostic Significance of the Bone Marrow-to-Aorta Uptake Ratio on 2-Deoxy-2-[18F]fluoro-d-glucose Positron Emission Tomography/Computed Tomography in Patients with Cholangiocarcinoma, Biomedicines, 2024-04, (국외)SCI
  11. Prognostic Impact of Visceral Adipose Tissue Imaging Parameters in Patients with Cholangiocarcinoma after Surgical Resection, INT J MOL SCI, 2024-03, (국외)SCI
  12. Development of a Prediction Model for Delirium in Hospitalized Patients with Advanced Cancer, Cancer Research and Treatment, 2024-02, (국외)SCI
  13. PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis, OncoImmunology, 2023-09, (국외)SCI
  14. PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis, OncoImmunology, 2023-09, (국외)SCI
  15. Systemic Delivery of a STING Agonist-Loaded PositivelyCharged Liposome Selectively Targets Tumor ImmuneMicroenvironment and Suppresses Tumor Angiogenesis, Small, 2023-06, (국외)SCI
  16. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial, LANCET, 2023-06, (국외)SCI
  17. Thyroid Dysfunction After Atezolizumab and Bevacizumab is Associated with Favorable Outcomes in Hepatocellular Carcinoma, Liver Cancer, 2023-05, (국외)SCI
  18. Multifunctional porous microspheres encapsulating oncolytic bacterial spores and their potential for cancer immunotherapy, Biomaterials Science, 2023-05, (국외)SCI
  19. ARID1A Mutation from Targeted NGS Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer, Cancer Research and Treatment, 2023-05, (국외)SCI
  20. ARID1A Mutation from Targeted NGS Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer, Cancer Research and Treatment, 2023-05, (국외)SCI
  21. High Levels of Antidrug Antibodies Against Atezolizumab as a Predictive Marker for Clinical Outcomes in Patients With Hepatocellular Carcinoma?Reply, JAMA Oncology, 2023-03, (국외)SCI
  22. High Levels of Antidrug Antibodies Against Atezolizumab as a Predictive Marker for Clinical Outcomes in Patients With Hepatocellular Carcinoma?Reply, JAMA Oncology, 2023-03, (국외)SCI
  23. High levels of baseline serum IL-10 are associated withreduced clinical benefit from first-line immunecheckpoint inhibitor therapy in advanced renal cellcarcinoma, Journal of Cancer, 2023-02, (국외)SCI
  24. High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma, Cancers, 2022-12, (국외)SCIE
  25. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab, Cancers, 2022-11, (국외)SCIE
  26. Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma, JAMA oncology, 2022-08, (국외)SCIE
  27. Prognostic implication of serum alpha-fetoprotein in patients with hepatocellular carcinoma treated with regorafenib, Future oncology (London, England), 2022-07, (국외)SCI
  28. Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?, Cancers, 2022-06, (국외)SCIE
  29. The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma, Therapeutic advances in medical oncology, 2022-06, (국외)SCI
  30. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade, Journal for immunotherapy of cancer, 2022-06, (국외)SCIE
  31. Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis, Therapeutic advances in medical oncology, 2022-04, (국외)SCIE
  32. Atezolizumab/bevacizumab vs. lenvatinib as first-line therapy for unresectable hepatocellular carcinoma: a real-world, multi-center study., Cancers, 2022-03, (국외)SCIE
  33. A prospective, multicenter, open-label study of the clinical efficacy of tapentadol extended-release in the treatment of cancer-related pain and improvement in the quality of life of opioid-naive or opioid-resistant patients, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022-03, (국외)SCIE
  34. A prospective, multicenter, open-label study of the clinical efficacy of tapentadol extended-release in the treatment of cancer-related pain and improvement in the quality of life of opioid-naive or opioid-resistant patients, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022-03, (국외)SCIE
  35. Deep learning model enables the discovery of a novel immunotherapeutic agent regulating the kynurenine pathway., Oncoimmunology(print), 2021-11, (국외)SCIE
  36. High endothelial venule is a surrogate biomarker for T-cell inflamed tumor microenvironment and prognosis in gastric cancer, Journal for immunotherapy of cancer, 2021-09, (국외)SCIE
  37. Combination Immunotherapies to Overcome Intrinsic Resistance to Checkpoint Blockade in Microsatellite Stable Colorectal Cancer, Cancers, 2021-09, (국외)SCIE
  38. Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients, Cancer, 2021-08, (국외)SCIE
  39. Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors, International Journal of Molecular Sciences, 2021-08, (국외)SCIE
  40. Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach, International Journal of Molecular Sciences, 2021-07, (국외)SCIE
  41. A Prognostic Model to Facilitate Palliative Care Referral in Oncology Outpatients, Cancer Research and Treatment, 2021-07, (국내)SCI
  42. "STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer", Journal for immunotherapy of cancer, 2021-06, (국외)SCIE
  43. Colonic Perforation After Treatment With Nivolumab in Esophageal Cancer: A Case Report, Annals of coloproctology, 2021-06, (국내)KCI
  44. Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: A multicentre retrospective study, Liver international : official journal of the International Association for the Study of the Liver, 2021-05, (국외)SCIE
  45. Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG), Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2021-02, (국외)SCIE
  46. Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with PD-1 blockade to suppress peritoneal carcinomatosis in colon cancer, Journal for immunotherapy of cancer, 2020-10, (국외)SCI
  47. Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors, International Journal of Molecular Sciences, 2020-10, (국외)SCIE
  48. Optimal Voltage and Electrical Pulse Conditions for Electrical Ablation to Induce Immunogenic Cell Death (ICD), Journal of Industrial and Engineering Chemistry, 2020-10, (국내)SCI
  49. Combination of Irreversible Electroporation and STING Agonist for Effective Cancer Immunotherapy, Cancers, 2020-10, (국외)SCI
  50. "A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer", British journal of cancer, 2020-08, (국외)SCI
  51. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity, Experimental and molecular medicine, 2020-07, (국외)SCI
  52. AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation, Lung cancer (Amsterdam, Netherlands), 2020-05, (국외)SCI
  53. Targeting Actomyosin Contractility Suppresses Malignant Phenotypes of Acute Myeloid Leukemia Cells, International Journal of Molecular Sciences, 2020-05, (국외)SCIE
  54. REACH-2: First Biomarker-Based Anti-Angiogenic Therapy in Patients With Advanced Hepatocellular Carcinoma, Chinese clinical oncology, 2020-01, (국외)기타
  55. Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer., Scientific reports, 2019-12, (국외)SCI
  56. "Sonic Hedgehog Pathway as the Prognostic Marker in Patients with Extensive Stage Small Cell Lung Cancer", Yonsei medical journal, 2019-08, (국내)SCIE
  57. STING signaling is a potential immunotherapeutic target in colorectal cancer, Journal of Cancer, 2019-07, (국외)SCIE
  58. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade, The Journal of clinical investigation, 2019-07, (국외)SCI
  59. Robotic transduodenal ampullectomy: A novel minimallyinvasive approach for ampullary neoplasms, The international journal of medical robotics + computer assisted surgery : MRCAS, 2018-12, (국외)SCI
  60. Randomized phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer, European journal of cancer (Oxford, England : 1990), 2018-12, (국외)SCI
  61. Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the efficacy of immune checkpoint blockade, Clinical cancer research : an official journal of the American Association for Cancer Research, 2018-11, (국외)SCI
  62. The Clinical Implications of FDG-PET/CT Differ According to Histology in Advanced Gastric Cancer, Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2018-06, (국외)SCI
  63. MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis, Journal of surgical oncology, 2018-04, (국외)SCI
  64. Predictive Nomogram for Recurrence of Stage I Colorectal Cancer After Curative Resection, Clinical colorectal cancer, 2018-03, (국외)SCI
  65. A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer, BMC cancer, 2018-03, (국외)SCIE
  66. A Case of Management for Advanced Hepatocellular Carcinoma with Extrahepatic Metastasis by Autologous Natural Killer Cells Combined with Immune Checkpoint Inhibitor , 대한간암학회지, 2018-01, (국내)SCOPUS
  67. PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer, Oncotarget, 2017-11, (국외)SCIE
  68. Baicalein inhibits tumor progression by inhibiting tumor cell growth and tumor angiogenesis, Oncology reports, 2017-09, (국외)SCIE
  69. Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery, BMC cancer, 2017-08, (국외)SCIE
  70. Emerging targeted therapies in advanced bladder cancer, Translational cancer research, 2017-03, (국외)SCIE
  71. Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab, Oncotarget, 2017-03, (국외)SCIE
  72. Prognostic Factors and Scoring Model for Survival in Metastatic Biliary Tract Cancer, Cancer Research and Treatment, 2017-01, (국외)SCI
  73. Different subtypes of epithelioid sarcoma and their clinical implication: long-term multi-institutional experience with a rare sarcoma, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2016-12, (국외)SCI
  74. Normalization of Tumor Vessels by Tie2 Activationand Ang2 Inhibition Enhances Drug Delivery andProduces a Favorable Tumor Microenvironment, Cancer cell, 2016-10, (국외)SCI
  75. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-08, (국외)SCI
  76. Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma, BMC cancer, 2016-06, (국외)SCIE
  77. Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients, BMC cancer, 2016-06, (국외)SCIE
  78. Rho GTPase RhoJ is Associated with Gastric Cancer Progression and Metastasis, Journal of Cancer, 2016-05, (국외)SCIE
  79. EGFR-mediated reactivation of MAPK signaling induces acquired resistance to GSK2118436 in BRAF V600E mutant NSCLC cell lines, Molecular cancer therapeutics, 2016-05, (국외)SCIE
  80. Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers., British journal of cancer, 2016-05, (국외)SCI
  81. Pilot Study of a Next-Generation Sequencing- Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution, PloS one, 2016-04, (국외)SCIE
  82. Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma, Annals of surgery, 2016-04, (국외)SCI
  83. Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium), Oncotarget, 2016-04, (국외)SCI
  84. Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer, BMC cancer, 2016-03, (국외)SCIE
  85. Assessment of Adrenal Function and Health-Related Quality of Life in Advanced Gastric Cancer Patients Who Received First-Line Chemotherapy., Oncology, 2016-02, (국외)SCI
  86. Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus, Oncotarget, 2016-01, (국외)SCIE
  87. Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites, Oncotarget, 2016-01, (국외)SCIE
  88. A multicenter phase II study of sorafenib in combination with erlotinibin patients with advanced non-small cell lung cancer (KCSG-0806), Lung cancer (Amsterdam, Netherlands), 2015-12, (국외)SCI
  89. Survivin silencing and TRAIL expression using oncolytic adenovirus increase anti-tumorigenic activity in gemcitabineresistant pancreatic cancer cells, Apoptosis : an international journal on programmed cell death, 2015-12, (국외)SCI
  90. Methylation-dependent regulation of HIF-1a stability restricts retinal and tumour angiogenesis, Nature communications, 2015-12, (국외)SCI
  91. A randomized phase II trial of ERCC1 and RRM1 mRNA expression?based chemotherapy versus docetaxel/carboplatin in advanced non?small cell lung cancer, Cancer chemotherapy and pharmacology, 2015-11, (국외)SCI
  92. Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma, Oncotarget, 2015-09, (국외)SCIE
  93. Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non?Small-Cell Lung Cancer: KCSG-LU05-04, American journal of clinical oncology, 2015-08, (국외)SCI
  94. Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma, Molecular cancer therapeutics, 2015-07, (국외)SCIE
  95. Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RETRearranged Lung Adenocarcinoma, Molecular cancer therapeutics, 2015-07, (국외)SCI
  96. An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer, European journal of cancer (Oxford, England : 1990), 2015-05, (국외)SCI
  97. Silencing Daxx increases the anti-tumor activity of a TRAIL/shRNA Bcl-xL-expressing oncolytic adenovirus through enhanced viral replication and cellular arrest, Cellular signalling, 2015-02, (국외)SCI
  98. Ratio of phosphorylated HSP27 to nonphosphorylated HSP27 biphasically acts as a determinant of cellular fate in gemcitabine-resistant pancreatic cancer cells, Cellular signalling, 2015-01, (국외)SCI
  99. The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer, Annals of surgical oncology, 2014-12, (국외)SCI
  100. Apoptosis of Surrounding Neurons by Brain tumor, 대한신경과학회지, 2001-05,
더보기
분당차병원 네트워크 닫기

미래형 의료기관 차움

국내의료기관

해외의료기관

대학

종합건진센터

차바이오그룹

  • 우수내시경실
    인증병원
  • 우수인공신장실
    인증병원
  • 의료계 최초
    국가품질상 수상
  • 보건복지부
    인증의료기관
  • 연구중심병원
    3회 연속지정
  • FERCAP
    국제인증 획득
  • 위암 치료 5회 연속
    적정성평가 1등급
  • 대장암 치료 6회 연속
    적정성평가 1등급
  • 유방암 치료 7회 연속
    적정성평가 1등급
  • 폐암 치료 5회 연속
    적정성평가 1등급

경기도 성남시 분당구 야탑로 59(야탑동) (우13496) 대표전화 031)780-5000

COPYRIGHT © 2021 CHAMC, ALL RIGHTS RESERVED.

CHA Network